Simulations Plus, Inc.

NASDAQ:SLP

Medical - Healthcare Information Services

Healthcare
$18.50 +0.11%

+$0.02 today

Market cap
$374.16M
Beta
1.32
P/E (TTM)
-5.9
EPS (TTM)
-$3.12
52W Low $11.09High $21.01

Volume 0.00M

Average 0.35M

SLP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Simulations Plus, Inc.NASDAQ: SLP

Research & Development · Q2 FY2026 · quarter ended Feb 2026

Research & development growth accelerates

Q2 FY2026 research & development of $3.47M rose 61.9% year over year, ahead of the +29.5% change in trailing-twelve-month research & development. Sequentially, it rose 16.4% from the prior quarter. Over 3 fiscal years it compounded at +29.0% a year.

Context

  • Research & development amounted to 8.7% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +61.9% holds above the trailing-twelve-month pace of +29.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterFeb 2026
$3.47M+16.4% QoQ
Last fiscal yearAug 2025
$6.88M+19.6% YoY
LTMFeb 2026
$9.34M+29.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+61.9%——
1 year+19.6%——
3-year CAGR+29.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
6.88M USD
Year-over-year change
+19.6%
4-year CAGR
+14.2%

Research & Development vs competitors

How SLP compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +29.5% is the 2nd highest of 9, against a peer median of -2.7%.
  • Research & development amounts to 11.6% of revenue for SLP, versus a peer median of 13.4%.
SLP Competitors
Research & Development for SLP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$94.68M USD+5.0%-1.4%139.0%
KRROKorro Bio, Inc.LTM Mar 2026$58.79M USD-15.8%+15.8%1530.1%
ANROAlto Neuroscience, Inc.LTM Mar 2026$55.94M USD+19.0%+24.4%—
ACIUAC Immune S.A.LTM Mar 2026CHF 52.18M CHF-17.6%-2.2%1409.6%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$35.89M USD+5.3%-1.7%44.2%
DHDefinitive Healthcare Corp.LTM Mar 2026$31.97M USD-10.4%-0.1%13.4%
SLPSimulations Plus, Inc.LTM Feb 2026$9.34M USD+29.5%+29.0%11.6%
OPRXOptimizeRx CorporationLTM Mar 2026$3.48M USD+1276.3%—3.2%
NAKANakamoto Inc.LTM Mar 2026$4 USD-100.0%—0.0%
AGLAgilon Health, Inc.LTM Mar 2026$0 USD——0.0%
NRCNational Research CorporationLTM Mar 2026$0 USD——0.0%
Peer median (excluding SLP) —-2.7%-0.7%13.4%

Competitors are the stored peer set for SLP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Aug 2023
FY2024
Aug 2024
FY2025
Aug 2025
Revenue46.47M53.91M59.58M70.01M79.18M
Cost of Revenue10.6M10.82M11.63M26.86M32.96M
Gross Profit35.87M43.08M47.95M43.15M46.22M
Gross Margin77.2%79.9%80.5%61.6%58.4%
Research & Development4.05M3.21M4.5M5.75M6.88M
Selling, General & Admin20.57M24.97M34.72M31.27M32.85M
Operating Expenses24.61M28.17M39.22M37.02M116.95M
Depreciation & Amortization3.59M3.57M3.84M5.67M8.21M
EBITDA14.7M18.69M13.07M18.08M14.7M
EBITDA Margin31.6%34.7%21.9%25.8%18.6%
Operating Income11.25M14.91M8.73M6.13M(70.73M)
Operating Margin24.2%27.7%14.6%8.8%-89.3%
Interest Income201K717K4.13M4.38M722K
Interest Expense22K0000
Other Income / Expenses(168K)204K2.97M6.28M1.35M
Income Before Tax11.09M15.12M11.7M12.41M(69.38M)
Pre-Tax Margin23.9%28.0%19.6%17.7%-87.6%
Income Tax Expense1.3M2.63M1.73M2.46M(4.66M)
Net Income9.78M12.48M9.96M9.95M(64.72M)
Net Margin21.1%23.2%16.7%14.2%-81.7%
EPS (Basic)0.490.620.500.50(3.22)
EPS (Diluted)0.470.600.490.49(3.22)
Weighted Avg Shares20.05M20.2M20.08M19.99M20.1M
Weighted Avg Shares (Diluted)20.74M20.75M20.47M20.3M20.1M

Simulations Plus, Inc.

NASDAQ:SLP

Intrinsic Alpha fair value

Locked

Current Price

$18.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.